On January 6th, 2013, the US Food and Drug Administration approved a new drug capable of slowing cognitive decline among patients with early stages or mild Alzheimer’s disease.
The drug, known as Leqembi, or lecanemab, was approved through an accelerated process.
“Alzheimer’s disease immeasurably incapacitates the lives of those who suffer from it and has devastating effects on their loved ones,” according to one FDA official.
The official described Leqembi as “the latest therapy to target and affect the underlying disease process of Alzheimer’s, instead of only treating the symptoms of the disease.”
In clinical trials, the drug was purported to slow cognitive decline among Alzheimer’s patients by up to 27 percent.
The trial data was published and available in the New England Journal of Medicine.
